TARRYTOWN, N.Y.--(BUSINESS WIRE)--Regulatory News:
EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) today confirmed that its engagement of SunTrust Robinson Humphrey to assist in exploring strategic alternatives to maximize the commercial opportunity of AmiKet™ includes the evaluation of potential transactions involving the sale of the Company. AmiKet™ is the Company’s prescription topical cream intended for the treatment of neuropathic pain. The engagement of SunTrust Robinson Humphrey will focus on the identification and implementation of a strategy designed to optimize AmiKet’s value for the Company’s shareholders.
EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) today confirmed that its engagement of SunTrust Robinson Humphrey to assist in exploring strategic alternatives to maximize the commercial opportunity of AmiKet™ includes the evaluation of potential transactions involving the sale of the Company. AmiKet™ is the Company’s prescription topical cream intended for the treatment of neuropathic pain. The engagement of SunTrust Robinson Humphrey will focus on the identification and implementation of a strategy designed to optimize AmiKet’s value for the Company’s shareholders.
